APA (7th ed.) Citation

Angioletta Lasagna, Dalila Mele, Federica Bergami, Domiziana Alaimo, Chiara Dauccia, Nicolò Alessio, . . . Irene Cassaniti. (2023). The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Angioletta Lasagna, et al. The Immunogenicity and the Safety of the Adjuvanted Glycoprotein E (gE)-based Recombinant Vaccine Against Herpes Zoster (RZV) in Cancer Patients During Immunotherapy. Taylor & Francis Group, 2023.

MLA (9th ed.) Citation

Angioletta Lasagna, et al. The Immunogenicity and the Safety of the Adjuvanted Glycoprotein E (gE)-based Recombinant Vaccine Against Herpes Zoster (RZV) in Cancer Patients During Immunotherapy. Taylor & Francis Group, 2023.